Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose intramuscular PRO051 study in Duchenne muscular dystrophy
NL-OMON21618Active, not recruiting
- Sponsor
- Prosensa
- Start
- Jun 2006
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of drisapersen in Duchenne muscular dystrophy (DMD), sponsored by Prosensa. Primary endpoint: Pharmacodynamics (dystrophin restoring effect). Started Jun 2006; status: active, not recruiting.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON21618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21618.